Clinical trials: Adenocarcinoma of Rectum
Colorectal Cancer
Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00016952
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- 15 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00544011
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Hopital Jean Minjoz
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Colorectal Cancer
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Palliative chemotherapy may help patients with advanced colorectal cancer live longer and more comfortably. PURPOSE: Randomized phase III trial to compare the effectiveness of and quality of life following three…
- Trial name
- NCT00002893
- Testing
- fluorouracil, leucovorin calcium, raltitrexed
- Where
- United Kingdom
- Volunteers
- 900 people
- Sponsor
- Medical Research Council
Rectal Adenocarcinoma, Rectal Cancer
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy.
- Trial name
- NCT07292298
- Testing
- High Rare Dose Rectal Brachytherapy Boost
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Locally Advanced Rectal Adenocarcinoma
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail
Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for mid-lower locally advanced rectal cancer - a single-center, single-arm, open-label…
- Trial name
- PICS (NCT06108596)
- Testing
- Sintilimab with Interleukin-2+CAPOX
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- BEBYP (NCT00720512)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 21 sites in Italy
- Volunteers
- 184 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00062426
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 52 sites in United States
- Sponsor
- Prologue Research International
Rectal Adenocarcinoma, Circulating Tumor DNA
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the…
- Conditions
- Rectal Adenocarcinoma, Circulating Tumor DNA, Minimal Residual Disease, Neoadjuvant Chemoradiotherapy
- Trial name
- NCT05969938
- Testing
- MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- WeiWei Xiao
Adenocarcinoma of Rectum
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer, with an objective response rate of about 70 %.
- Trial name
- NCT01674309
- Testing
- FOLFORINOX
- Where
- 37 sites in France
- Volunteers
- 65 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Rectal Cancer, Neoplasm Metastasis
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Panitumumab is a monoclonal antibody. It works by attaching to a protein called epidermal growth factor receptor found on normal and cancer cells.
- Trial name
- NCT00346099
- Testing
- Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation
- Sponsor
- NSABP Foundation Inc
Rectal Adenocarcinoma, Rectal Cancer
Asian Watch-and-Wait Database (AWWD)
The standard treatment approach of localized rectal adenocarcinoma involves neoadjuvant radiotherapy and chemotherapy followed by assessment for surgery and optional adjuvant chemotherapy.
- Trial name
- AWWD (NCT06631443)
- Where
- India
- Volunteers
- 337 people
- Sponsor
- Tata Memorial Centre
Locally Advanced Rectal Carcinoma
Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer
The goal of this clinical trial is to test the efficacy and safety in patients with locally advanced middle and lower rectal cancer.
- Trial name
- NeoCaCRT (NCT05792735)
- Testing
- Cadonilimab Injection, Short-course radiotherapy, Consolidation chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Shenzhen People's Hospital
Colon or Upper Rectum Adenocarcinoma
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
Phase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment…
- Trial name
- CIRCULATE PAC (NCT06197425)
- Testing
- "FOLFIRI" cures, Trifluridine cures, BIOLOGICAL ASSESSMENT
- Where
- France
- Volunteers
- 1,660 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Cancer, Metastatic Cancer
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
The purpose of this study is to find the highest dose that can be given safely to people who have had liver disease resected. This is a Phase I study.
- Trial name
- NCT00059930
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Non-Metastatic Adenocarcinoma of the Rectum
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
Background: The investigational anti-cancer drug Selumetinib (AZD6244) prevents a protein found in rectal cancer from working properly, which may slow tumor growth and allow radiation and chemotherapy treatments to destroy more…
- Trial name
- NCT01134601
- Testing
- Radiation Therapy, Capecitabine, AZD6244
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Rectal Carcinoma
A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection
This study targets patients undergoing ultra-low rectal cancer surgery, which requires internal sphincter resection for sphincter-saving procedures.
- Trial name
- STAR-TAR (NCT06662643)
- Testing
- Delayed transanal pull-through anastomosis, Direct Anastomosis Plus Prophylactic Ileostomy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhongnan Hospital
Colorectal Cancer
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182715
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 2,421 people
- Sponsor
- Velindre NHS Trust
Locally Advanced Rectal Carcinoma
Radiological Markers in Locally Advanced Rectal Cancer
The goal of this observational study is to evaluate the prognostic significance of radiological markers, including the Likert Score derived from diffusion-weighted MRI (DWI), in patients with locally advanced rectal cancer (LARC)…
- Trial name
- LARC (NCT06843655)
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- IRCCS San Raffaele